Notre-Dame Hospital, Paris Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2002
NCT00168181
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Alternative names

Notre-dame Hospital | Notre-Dame Hospital (CHUM)

Active Ingredients

Drugs in Phase 3 Trials (1)

pilocarpine (ocusert) (1 trial)

Drugs in Phase 2 Trials (3)

carboplatin (paraplatin) (1 trial)

ipilimumab (yervoy) (1 trial)

paclitaxel (taxol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Head and Neck Neoplasms (Phase 3)

Melanoma (Phase 2)

Xerostomia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 4